Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the Licensed 7vCRM Vaccine

Abstract

PHiD-CV induces ELISA and functional OPA antibodies for all vaccine serotypes after primary vaccination and is noninferior to 7vCRM in terms of ELISA and/or OPA threshold responses. Effective priming is further indicated by robust booster responses.

Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial

“…A parallel acute otitis media (AOM) trial conducted by the Tampere University Vaccine Research Centre (TAUVRC) had the same cluster-randomised design and its subjects were also evaluated in this study. 13 …”

“…[4][5][6][7] Another pneumococcal vaccine containing ten serotype-specific polysaccharides conjugated to Haemophilus influenzae protein D, tetanus toxoid and diphtheria toxoid as the carrier proteins was developed (PHiD-CV10). [8][9][10] It was licensed in EU in March 2009 (Synflorix™, GlaxoSmithKline Vaccines) based on PHiD-CV10 immunological data according to criteria recommended by WHO 11 for licensure for protection against IPD, PHiD-CV10 safety data, and efficacy results of the 11-valent precursor formulation against acute otitis media. 12 The Finnish Invasive Pneumococcal disease (FinIP) vaccine trial was designed to demonstrate the clinical vaccine effectiveness (VE) of PHiD-CV10 against IPD.…”

Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial

“…The Tampere University Vaccine Research Centre (TAUVRC) undertook a parallel trial with the same design for acute otitis media, and its participants were also followed up for the outcomes of this study. 5 The trial design has been previously described. 4 Briefly, children younger than 19 months could be enrolled if they had not received and were not anticipated to receive any of the study vaccines and had no general contraindications to vaccinations.…”

Changing trends in serotype distribution and antimicrobial susceptibility ofStreptococcus pneumoniaecausing invasive diseases in Central Thailand, 2009–2012

“…Of these serotypes, 15A, 23A, 35B, and 6C were the most common among penicillin-nonsusceptible isolates from population-based invasive pneumococcal surveillance in the United States during 2007. 16 The emergence of non-PCV7 serotypes led to the development and introduction of broader PCVs: a 10-valent vaccine (PCV10)-PCV7 with serotypes 1, 5, and 7F added 17,18 ; and a 13-valent vaccine (PCV13)-PCV10 with serotypes 3, 6A, and 19A added. 19 Recently, the 15-valent vaccine (PCV15) with serotypes 22F and 33F added to PCV13, has been tested in clinical trials.…”